THBS1 and pulmonary arterial hypertension: Another can be as nanocarriers coated with multiple active DRP molecules, designed for systemic administration and capable of scavenging and eliminating pathological TSP1-plasma levels, which are generally implicated in acute clinical conditions such as cerebrovascular or myocardial IRI and PAH.